ReShape Lifesciences Reports Third Quarter and Nine Month 2021 Financial and Operational Results
Recent Highlights and Accomplishments
- Achieved revenue growth for the nine months and third quarter of 29.2% and 2.9% respectively, compared to the same periods the prior year
- Consecutively succeeded in sequential quarterly revenue growth of 5.1% from the second quarter to third quarter
- Launched the Company’s first and largest multi-platform consumer marketing campaign
- Rolled out line of supplements on ReShape Marketplace™ to meet consumers’ nutritional needs
- Strengthened operations and commercial teams with the addition of key personnel, including
Al Diaz , Vice President of Operations and Research & Development - Secured key international regulatory and labeling approvals as part of the manufacturing transition to the company’s direct control in the
U.S.
Financial Section
Note for metrics analysis: In the third quarter, the Company experienced substantial increases in sales and marketing, general and administrative, R&D, and total operating expenses due to the issuance of non-cash stock-based compensation for the first time since 2017, and costs related to the acquisition of Obalon. Given that these expenses are specific in nature and uniquely attributed to the significant milestones achieved this year, the Company expects its expenditure to revert to normal moving forward considering these charges are non-recurring and generally recognized as one-time charges. Notably, non-cash stock-based compensation for the three months ended
Third Quarter Ended
Revenue for the three months ended September 30, 2021 was $3.7 million compared to
Gross profit for the third quarter of 2021 was $2.1 million compared to $2.3 million for the three months ended September 30, 2020. The
Sales and marketing expenses for the three months ended September 30, 2021 were
General and administrative expenses were
Research and development expenses were
Total operating expenses were
Non-GAAP adjusted EBITDA loss was
Nine Months Ended
Revenues for the nine months ended
Gross profit for the nine months ended
General and administrative expenses for the nine months ended
Research and development expenses decreased by
Sales and marketing expenses for the nine months ended
With regard to the one-time expenses and other factors mentioned above, the Company’s total operating expenses for the nine months ended
On a Non-GAAP adjusted EBITDA basis, the Company reported a loss of
Cash and cash equivalents were
Webinar Information
Management will post a webinar discussing ReShape’s financial and operational results today at 8:45 a.m. ET. The link to the webinar is here and will be available on the Investor Relations page of the ReShape Lifesciences, Inc. website, https://ir.reshapelifesciences.com/.
ABOUT RESHAPE LIFESCIENCES INC.
ReShape Lifesciences™ is America's premier weight loss and metabolic health-solutions company, offering an integrated portfolio of proven products and services that manage and treat obesity and metabolic disease. The FDA-approved Lap-Band® Program provides minimally invasive, long-term treatment of obesity and is an alternative to more invasive surgical stapling procedures such as the gastric bypass or sleeve gastrectomy. The ReShape Vest™ System is an investigational (outside the U.S.) minimally invasive, laparoscopically implanted medical device that wraps around the stomach, emulating the gastric volume reduction effect of conventional weight-loss surgery. It helps enable rapid weight loss in obese and morbidly obese patients without permanently changing patient anatomy. reshapecare™ is a virtual weight-management program that supports lifestyle changes for all weight-loss patients led by board certified health coaches to help them keep the weight off over time. The recently launched ReShape Marketplace™ is an online collection of quality wellness products curated for all consumers to help them achieve their health goals.
Forward-Looking Safe Harbor Statement
This press release may contain forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Actual results could differ materially from those discussed due to known and unknown risks, uncertainties, and other factors. These and additional risks and uncertainties are described more fully in the company's filings with the
Non-GAAP Disclosures
In addition to the financial information prepared in conformity with GAAP, we provide certain historical non-GAAP financial information. Management believes that these non-GAAP financial measures assist investors in making comparisons of period-to-period operating results and that, in some respects, these non-GAAP financial measures are more indicative of the Company's ongoing core operating performance than their GAAP equivalents.
Management believes that the presentation of this non-GAAP financial information provides investors with greater transparency and facilitates comparison of operating results across a broad spectrum of companies with varying capital structures, compensation strategies, derivative instruments, and amortization methods, which provides a more complete understanding of our financial performance, competitive position, and prospects for the future. However, the non-GAAP financial measures presented in this Form 10-K have certain limitations in that they do not reflect all of the costs associated with the operations of our business as determined in accordance with GAAP. Therefore, investors should consider non-GAAP financial measures in addition to, and not as a substitute for, or as superior to, measures of financial performance prepared in accordance with GAAP. Further, the non-GAAP financial measures presented by the Company may be different from similarly named non-GAAP financial measures used by other companies.
Adjusted EBITDA
Management uses Adjusted EBITDA in its evaluation of the Company's core results of operations and trends between fiscal periods and believes that these measures are important components of its internal performance measurement process. Adjusted EBITDA is defined as net loss before interest, taxes, depreciation and amortization, stock-based compensation, changes in fair value of liability warrants and other one-time costs. Management uses Adjusted EBITDA in its evaluation of the Company's core results of operations and trends between fiscal periods and believes that these measures are important components of its internal performance measurement process. Therefore, investors should consider non-GAAP financial measures in addition to, and not as a substitute for, or as superior to, measures of financial performance prepared in accordance with GAAP. Further, the non-GAAP financial measures presented by the Company may be different from similarly named non-GAAP financial measures used by other companies.
CONTACTS
ReShape Lifesciences Investor Contact:
Chief Financial Officer
949-276-6042
ir@ReShapeLifesci.com
Investor Contact:
862-213-1398
dboateng@dkbpartners.net
Condensed Consolidated Balance Sheets
(dollars in thousands; unaudited)
2021 | 2020 | |||||||
ASSETS | ||||||||
Current assets: | ||||||||
Cash and cash equivalents | $ | 29,243 | $ | 2,957 | ||||
Restricted cash | 50 | 50 | ||||||
Accounts and other receivables | 3,457 | 2,620 | ||||||
Inventory | 3,206 | 2,244 | ||||||
Prepaid expenses and other current assets | 1,633 | 1,073 | ||||||
Total current assets | 37,589 | 8,944 | ||||||
Property and equipment, net | 1,602 | 584 | ||||||
Operating lease right-of-use assets | 450 | 465 | ||||||
Other intangible assets, net | 28,469 | 27,022 | ||||||
21,053 | — | |||||||
Other assets | 1,535 | 46 | ||||||
Total assets | $ | 90,698 | $ | 37,061 | ||||
LIABILITIES AND STOCKHOLDERS’ EQUITY | ||||||||
Current liabilities: | ||||||||
Accounts payable | $ | 3,112 | $ | 3,655 | ||||
Accrued and other liabilities | 3,235 | 3,630 | ||||||
Warranty liability, current | 545 | 397 | ||||||
Debt, current portion, net of deferred financing costs | 2,971 | 3,609 | ||||||
Operating lease liabilities, current | 473 | 314 | ||||||
Total current liabilities | 10,336 | 11,605 | ||||||
Debt, noncurrent portion | — | 9,168 | ||||||
Operating lease liabilities, noncurrent | — | 163 | ||||||
Warranty liability, noncurrent | 527 | 1,022 | ||||||
Deferred income taxes | 615 | 615 | ||||||
Total liabilities | 11,478 | 22,573 | ||||||
Commitments and contingencies | ||||||||
Stockholders’ equity: | ||||||||
Preferred stock: | ||||||||
Series B convertible preferred stock | — | — | ||||||
Series C convertible preferred stock | — | 1 | ||||||
Common stock | 18 | 6 | ||||||
Additional paid-in capital | 620,611 | 529,429 | ||||||
Accumulated deficit | (541,302 | ) | (514,827 | ) | ||||
Accumulated other comprehensive loss | (107 | ) | (121 | ) | ||||
Total stockholders’ equity | 79,220 | 14,488 | ||||||
Total liabilities and stockholders’ equity | $ | 90,698 | $ | 37,061 | ||||
Condensed Consolidated Statements of Operations
(dollars in thousands, except per share amounts; unaudited)
Three Months Ended |
Nine Months Ended |
|||||||||||||||
2021 | 2020 | 2021 | 2020 | |||||||||||||
Revenue | $ | 3,708 | $ | 3,602 | $ | 10,458 | $ | 8,092 | ||||||||
Cost of revenue | 1,573 | 1,321 | 3,886 | 3,471 | ||||||||||||
Gross profit | 2,135 | 2,281 | 6,572 | 4,621 | ||||||||||||
Operating expenses: | ||||||||||||||||
Sales and marketing | 3,496 | 1,160 | 6,186 | 3,446 | ||||||||||||
General and administrative | 12,052 | 2,434 | 19,085 | 7,809 | ||||||||||||
Research and development | 1,571 | 859 | 2,245 | 2,619 | ||||||||||||
Total operating expenses | 17,119 | 4,453 | 27,516 | 13,874 | ||||||||||||
Operating loss | (14,984 | ) | (2,172 | ) | (20,944 | ) | (9,253 | ) | ||||||||
Other expense (income), net: | ||||||||||||||||
Interest expense, net | 33 | 739 | 804 | 1,632 | ||||||||||||
Warrant expense | 2,813 | — | 2,813 | — | ||||||||||||
Loss on extinguishment of debt, net | — | 2,435 | 2,061 | 2,435 | ||||||||||||
Gain on foreign currency exchange, net | (101 | ) | (128 | ) | (170 | ) | (118 | ) | ||||||||
Loss before income tax provision | (17,729 | ) | (5,218 | ) | (26,452 | ) | (13,202 | ) | ||||||||
Income tax expense (benefit) | (30 | ) | (39 | ) | 23 | (108 | ) | |||||||||
Net loss | $ | (17,699 | ) | $ | (5,179 | ) | $ | (26,475 | ) | $ | (13,094 | ) | ||||
Net loss per share - basic and diluted: | ||||||||||||||||
Net loss per share - basic and diluted | $ | (1.48 | ) | $ | (1.32 | ) | $ | (2.51 | ) | $ | (3.36 | ) | ||||
Shares used to compute basic and diluted net loss per share | 11,997,370 | 3,927,986 | 10,546,683 | 3,896,964 | ||||||||||||
The following table contains a reconciliation of non-GAAP net loss to GAAP net loss attributable to common stockholders for the three and nine months ended
Three Months Ended |
Nine Months Ended |
||||||||||||||
2021 | 2020 | 2021 | 2020 | ||||||||||||
GAAP net loss | $ | (17,699 | ) | $ | (5,179 | ) | $ | (26,475 | ) | $ | (13,094 | ) | |||
Adjustments: | |||||||||||||||
Interest expense, net | 33 | 739 | 804 | 1,632 | |||||||||||
Income tax expense (benefit) | (30 | ) | (39 | ) | 23 | (108 | ) | ||||||||
Depreciation and amortization | 548 | 419 | 1,416 | 1,257 | |||||||||||
Stock-based compensation expense | 10,720 | 255 | 10,457 | 1,029 | |||||||||||
Loss on extinguishment of debt, net | — | 2,435 | 2,061 | 2,435 | |||||||||||
Warrant expense | 2,813 | — | 2,813 | — | |||||||||||
Professional fees incurred in connection with the Obalon merger | — | — | 2,277 | — | |||||||||||
Non-GAAP loss | $ | (3,615 | ) | $ | (1,370 | ) | $ | (6,624 | ) | $ | (6,849 | ) | |||
Source: ReShape Lifesciences Inc